TheraRadar

Pharma Intelligence, Simplified

← Back
Data updated: Mar 10, 2026

CYCLE

OncologyNeurologyCardiovascular
Generics

CYCLE is a generic drug manufacturer focused on Oncology, Neurology, Cardiovascular. Key products include TASCENSO ODT.

1975
Since
11
Drugs
-
Trials
56
Approved (2yr)

Key Drugs

TASCENSO ODT
fingolimod lauryl sulfate
CNS
S1PR1 4 indications · 2021
HARLIKU
nitisinone
HPD 1 indications · 2017
NITYR
nitisinone
4-hydroxyphenyl-pyruvate dioxygenase 1 indications · 2017

Recent Activity

CHLORPROMAZINE HYDROCHLORIDE 2026-01-26
CHLORPROMAZINE HYDROCHLORIDE 2025-10-10
PIROXICAM 2025-09-12
Labeling
QUINIDINE SULFATE 2025-08-21
Labeling
QUINIDINE SULFATE 2025-07-29
Labeling
INDOMETHACIN 2025-07-03
HARLIKU 2025-06-10
Efficacy
INDOMETHACIN 2025-06-02
Labeling
CHLORPROMAZINE HYDROCHLORIDE 2025-04-25
INDOMETHACIN 2025-02-24
SEC Filings Pro
Loading...

Therapeutic Focus

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Oncology 38%
0 drugs Phase 2: 3 Phase 1: 3
Neurology 25%
1 drugs
Cardiovascular 17%
0 drugs Phase 2: 2
Metabolic 17%
0 drugs Phase 2: 2
Gastroenterology 4%
0 drugs Phase 1: 1

Pipeline Strength Pro

Loading...

Competitors Pro

Takeda big-pharma
Oncology, Gastroenterology, Neurology, Metabolic
Merck big-pharma
Oncology, Cardiovascular, Metabolic
Novo Nordisk big-pharma
Metabolic, Oncology, Cardiovascular, Neurology
Johnson & Johnson big-pharma
Oncology, Cardiovascular, Metabolic
Amgen biotech
Oncology, Metabolic, Gastroenterology, Neurology